Psoriatic Arthritis Clinical Trials

A listing of Psoriatic Arthritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Efficacy Safety and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been

apremilast
  • 265 views
  • 09 Jun, 2021
  • 191 locations
Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Observation has pointed out, that osteitis present in the MRI scans, predicts bone erosion and that this in accordance with the concept by underlining the importance of bone marrow involvement in arthritis [Krabben A, 2013]. Abatacept with its favourable safety profile preferentially interrupts activation of nave T cells and perhaps …

  • 0 views
  • 24 Jan, 2021
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF na ve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF nave subjects with active PsA .

  • 0 views
  • 11 Jun, 2021
  • 14 locations
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic

  • 0 views
  • 09 Jun, 2021
  • 28 locations
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease

This is a phase I study of guselkumab, a humanized anti-IL23 monoclonal antibody, for patients with alcoholic liver disease. This drug is approved for the use in psoriatic arthritis but not for

  • 0 views
  • 12 May, 2021
  • 1 location
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes

other conditions such as rheumatoid arthritis and psoriatic arthritis, anti-TNF treatment has failed to demonstrate any benefit on the structural progression of AS, some data even suggesting that it may

arthritis
rheumatic diseases
NSAID
rheumatism
tumor necrosis factor
  • 91 views
  • 05 Feb, 2021
  • 25 locations
Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

emerged as a new option for the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, skin disorders and others. CPL409116 inhibits JAK1 and

  • 0 views
  • 27 Jan, 2021
  • 1 location
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

will follow the "Treat-to-Target" principle. This approach already demonstrated its benefit in rheumatoid arthritis or in psoriatic arthritis. This concept was also suggested for axSpA with low levels

secukinumab
tnf blocker
adalimumab
anti-rheumatic drugs
monoclonal antibodies
  • 17 views
  • 25 Jan, 2021
  • 26 locations
Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA in Healthy Adults

with Crohn's disease, Ulcerative Colitis, plaque psoriasis and psoriatic arthritis. Stelara is an immune suppressant that reduces the effects of inflammatory proteins within the body. This is

plaque psoriasis
arthritis
ustekinumab
  • 0 views
  • 09 Jun, 2021
  • 3 locations
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade

The SPARTACUS study will explore the therapeutic efficacy of 2 different treatment strategies for patients suffering from peripheral Spondyloarthritis (pSpA), classified according to the "Assessment in SpondyloArthritis international Society" (ASAS) classification criteria; it will be set up as a 48-week, prospective, randomized, active-comparator controlled, double-blind, double-dummy, clinical trial with a …

  • 0 views
  • 24 Feb, 2021
  • 6 locations